Biotechnology

Filter

Current filters:

None

Popular Filters

2301 to 2325 of 2510 results

FDA backs Roche's personalized breast cancer therapy Perjeta

11-06-2012

The US Food and Drug Administration on Friday approved Swiss drug major Roche (ROG: SIX) subsidiary Genentech's…

BiotechnologyGenentechNorth AmericaOncologyPerjetapertuzumabPharmaceuticalRegulationRoche

Amgen's Sensipar/Mimpara fails to meet endpoint in CV events for dialysis patients

11-06-2012

Amgen (Nasdaq: AMGN), the world's largest independent biotech company, announced top-line results on…

AmgenBiotechnologyCardio-vascularMimparaNephrology and HepatologyResearchSensipar

1,000th designation of an orphan medicinal product in EU

10-06-2012

According to a European Commission statement, over 30 million European citizens suffer from a rare disease.…

BiotechnologyEuropePharmaceuticalRare diseasesRegulation

Nearly a-quarter of European countries do not provide access to biologics for arthritis

08-06-2012

Data from a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism…

Anti-Arthritics/RheumaticsBiotechnologyEuropeMarkets & MarketingPricing

Merck KGaA collaborates with Dr Reddy's on biosimilars

07-06-2012

With the aim of capitalizing on the batch of patent expires for blockbuster biotechnology-based drugs…

BiotechnologyDr Reddy's LaboratoriesGenericsMarkets & MarketingMerck KGaAMerck SeronoOncologyResearch

KYTHERA Biopharma gets $33.3 million in payments from Bayer

07-06-2012

Privately-held US biotech firm KYTHERA Biopharmaceuticals says it has received a $15.8 million payment…

BayerBiotechnologyFinancialKYTHERA BiopharmaceuticalsLicensingPharmaceuticalResearch

Reimbursement outlook for DMT Alzheimer's therapies in Europe

06-06-2012

Emerging potentially disease-modifying therapies (DMTs) for Alzheimer's disease will likely be reimbursed…

BiotechnologyEuropeMarkets & MarketingNeurologicalPharmaceuticalPricing

UK pharma industry head fears for future of UK medical research

06-06-2012

The UK government is too focused on encouraging "breakthrough drugs" at the expense of significant gains…

BiotechnologyEuropePharmaceuticalPoliticsPricingResearch

Enterologics aims to produce Rx biotherapeutics for GI diseases

05-06-2012

USA-based biotech firm Enterologics (OTCBB: ELGO.OB), which is focussed on the development of live biotherapeutic…

BiotechnologyEnterologicsGastro-intestinalsNorth AmericaResearch

Zacks analysts view progress of GSK bid for Human Genome Sciences

05-06-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) recently announced that the waiting period with respect to…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Onyx Pharma links with Texas MD Anderson Cancer Center on research

05-06-2012

US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) and The University of Texas MD Anderson Cancer Center…

BiotechnologycarfilzomibOncologyOnyx PharmaceuticalsoprozomibResearch

Rindopepimut likely to be Rxed by 36% of surveyed US oncologists for GMB patients

05-06-2012

US oncologists surveyed by advisory firm Decision Resources indicate that they would prescribe the emerging…

BiotechnologyCelldex TherapeuticsMarkets & MarketingNorth AmericaOncologyPharmaceuticalrindopepimut

NicOx drops its option to take full ownership of Altacor

04-06-2012

French biotechnology firm NicOx (NYSE Euronext Paris: COX) said last Friday that its board of directors…

AltacorBiotechnologyMergers & AcquisitionsNicOxOphthalmics

EMA boosts EU transparency with on-line publication of suspected side effect reports

31-05-2012

The European Medicines Agency yesterday began publishing suspected side effect reports for medicines…

BiotechnologyEuropePharmaceuticalRegulation

Alnylam's RSV drug candidate misses primary endpoint in Ph IIb

31-05-2012

Leading USA-based RNAi therapeutics firm Alnylam Pharmaceuticals (Nasdaq: ALNY) yesterday announced disappointing…

Alnylam PharmaceuticalsBiotechnologyResearchRespiratory and Pulmonary

BioAlliance's Sitavig NDA "receivable" by US FDA

30-05-2012

French biotech firm BioAlliance Pharma (Euronext Paris: BIO) has announced the receivability of its Sitavig…

Anti-viralsBioAlliance PharmaBiotechnologyNorth AmericaRegulationSitavigSitavir

Expanded Access Program for enzalutamide agreed with US FDA

30-05-2012

The US Food and Drug Administration agreed that Medivation (Nasdaq: MDVN) and Japanese drug major Astellas…

Astellas PharmaBiotechnologyenzalutamideMDV3100MedivationNorth AmericaOncologyPharmaceuticalRegulation

2301 to 2325 of 2510 results

COMPANY SPOTLIGHT

Menarini

Back to top